About Luye Pharma Boston R&D
The Cutting Edge of Oncologoical, Neurological, and Metabolic Treatments
Next generation treatments are constantly evolving as researchers continue to reveal the intracacies of pathologies and leverage this knowledge to discover novel therapeutic approaches. Luye Boston R&D is commited to leading the evolution of these treatments by pursuing innovative research technologies driven by our deep understanding of pathways, targets, and novel drug delivery systems.
Luye Pharma: Global Presence
The company has established R&D centers in China, the U.S. and Europe with a professional and global R&D team of over 420 people, focusing on new drug development in the therapeutic areas of CNS, oncology, cardiovascular and metabolism.
Luye Boston R&D Collaborations
The Luye Team
Xi-Yong (Sean) Fu, President
Dr. Xi-Yong Fu is the President of Luye Boston R&D LLC. Prior to joining Luye, Dr. Fu was the President of Cureport Inc., a VC backed biotech start-up specialized in liposomal drug delivery technology. Before that, Dr. Fu worded at Merck & Co., for 15 years with extensive experiences in R&D, business development, finance and operational management. Dr. Fu led the integration of global discovery and preclinical R&D network following the landmark $42B merger between Merck and Schering-Plough. Dr. Fu participated and contributed to over 30 novel drug development programs including ISENTRESS® for HIV/AIDS and ZEPATIER® for chronic HCV infection.
Dr. Fu earned his PhD from The Ohio State University and his MBA from the Wharton School of Business.
Xinyu (Tom) Huang, Vice President, Forumlation
Dr. Huang received his B.S. in chemistry from Jilin University in 1994 and M.S. in organic chemistry from Shanghai Institute of Organic Chemistry, Academia Sinica in 1997. Then he came to United states and got his PhD. in polymer chemistry from University of Akron in 2002. After working as a postdoc researcher in Electrical Engineering Department at Princeton University for 2 years, Dr. Huang started his industrial journey in 2004. Dr. Huang has worked for Ciba, Lonza, Teva and Klus Pharma. He has expertise in formulation development in many dosage forms including oral solids, injectable, transdermal patch, buccal/sublingual film and virginal ring. Dr. Huang joined Luye Pharma in May 2017.
Tim Maguire, Director, Business Development
Dr. Maguire is currently the Director of Business development at Luye USA, Boston. Prior to joining Luye Boston R&D, Dr. Maguire a principal and managing director at Vicara Capital. Dr. Maguire has also worked in the medical device and pharmaceutical industries for over 15 years in various roles of increased leadership and responsibility. These included positions within strategy, global manufacturing, business development, clinical R&D, and commercial teams. He has extensive experience in global product launches and life-cycle management.
Dr. Li Zhou, PhD, VP of Antibody Research and CAR-T therapy
Li Zhou, PhD, VP of Antibody Research and CAR-T therapy at Luye Boston R&D center. Before this, he was VP of CAR-T Cell Therapy at Livzon Mabpharm in Zhuhai Guangdong. He helped building the lentivector and CAR-T GMP manufacturing platforms and advanced the first internal CAR-T program into the IND enabling clinical study. He was previously VP of Cell Engineering at TxCell (now is Sangamo therapeutics) in France. He led the team quickly established a diverse CAR-Treg product pipeline for treating autoimmune disease and organ transplant rejection. His team helped advancing the first-ever CAR-Treg clinical trial for prevention of organ transplant rejection. As CSO and Director of Research at ZMKS international Cancer Therapy Biotechnologies Co., he pioneered the effort in engineering the armed CAR-T cells that can secrete bispecific checkpoint inhibitor antibodies. Prior to this, he was investigator III/lab head in Novartis Biologics Center in Cambridge working on developing bispecific antibody therapeutics, and CAR-T therapies in collaboration with Dr Carl June at UPenn. He led a number of CAR-T programs including CD22 CAR-T, bispecific CD19/CD22 CAR-T to treat antigen negative relapse in blood cancers, and Mesothelin CAR-T against solid tumors. Top candidates are currently in clinical development at Novartis. He also led the program on developing on-switch regulatable CAR-T.
Dr. Jason Zhang
Dr. Jason Jingxin Zhang is the Vice President of nucleic acid and gene therapy. Jason has more than 15 years’ drug discovery experiences in oncology, immunology, hepatic, neuromuscular and neurology disease areas, with modalities covering small molecules, antibodies, oligonucleotides, mRNAs and viral gene therapies. Most recently, Dr. Zhang was a Sr. Director at WAVE Life Sciences leading teams moving multiple drug candidates into clinical trials, as well as leading major collaborations including with University of Oxford, Pfizer, and Deep Genomics. He was one of the lead scientists developing and significantly enhancing its stereochemistry drug development platforms. Prior to Wave, Dr. Zhang was a Lab head at Sanofi developing therapeutics in Oncology & Onco-immunology. Before that, he was at Novartis Oncology developing DR5 therapeutic antibody and its biomarkers. Dr. Zhang holds a Ph.D. degree in Organic and Medicinal Chemistry from Peking Union Medical College with Prof. Xiaotian Liang in Beijing, and a Ph.D. degree in Immunology and Pharmacology from New York University School of Medicine with Dr. Dan Littman; and he conducted postdoctoral research in biology at Harvard University and Novartis and in chemistry at Yale University.